Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 5Diarrhea 3Vulvar Neoplasms 1Vulvar Diseases 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma, Alveolar Soft Part 1Recurrence 1Rectal Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Low Anterior Resection Syndrome 1Gliosarcoma 1Glioblastoma 1Exanthema 1Colitis 1Carcinoma in Situ 1

Interventions

pembrolizumab 4Nivolumab 4fludarabine 3aldesleukin 3Ipilimumab 3Cyclophosphamide 3vedolizumab 2enfortumab vedotin 2darolutamide 2cabozantinib 2atezolizumab 2Specimen Handling 2Riluzole 2Prednisone 2Magnetic Resonance Spectroscopy 2LDP-02 2Infliximab 2Immunoglobulin G 2Fecal Microbiota Transplantation 2Disulfides 2CTLA-4 Antigen 2CT-P13 2Biopsy 2relatlimab 1prednylidene 1palbociclib 1olaparib 1gallium 68 PSMA-11 1deltacortene 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Loperamide × 1 year × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡